Assessment of circulating tumor cells (CTCs) in prostate cancer patients with low-volume tumors

Pathology International

Volumn 60, Issue 10, 2010, Pages 667-672

  Ali, Amina ^a,b   Furusato, Bungo ^b,c   Ts'O, Paul O P ^d   Lum, Zhao Ping ^d   Elsamanoudi, Sally ^a,b   Mohamed, Ahmed ^a,b   Srivastava, Shiv ^b   Moul, Judd W ^e   Brassell, Stephen A ^a,b   Sesterhenn, Isabell A ^c   McLeod, David G ^a,b  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^c Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

^d CCC Diagnostics LLC   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

circulating tumor cells; CTCs; insignificant; prostate cancer; small volume

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE DISTRIBUTION; ARTICLE; BLOOD SAMPLING; CANCER GRADING; CANCER INCIDENCE; CANCER PATIENT; CANCER STAGING; CONTROLLED STUDY; FOLLOW UP; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RACE; TUMOR CELL; TUMOR VOLUME; WEIGHT;

ADULT; AGED; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MALE; MIDDLE AGED; NEOPLASTIC CELLS, CIRCULATING; PROSTATECTOMY; PROSTATIC NEOPLASMS; TUMOR BURDEN;

EID: 77956839562     PISSN: 13205463     EISSN: 14401827     Source Type: Journal    
DOI: 10.1111/j.1440-1827.2010.02584.x     Document Type: Article

References (23)

1. Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whittemore AS, Schmid HP. Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 1993 71 : 933 8.
2. Chan TY, Chan DY, Stutzman KL, Epstein JI. Does increased needle biopsy sampling of the prostate detect a higher number of potentially insignificant tumors? J Urol 2001 166 : 2181 4.
3. Epstein JI, Chan DW, Sokoll LJ et al. Nonpalpable stage T1c prostate cancer: Prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol 1998 160 : 2407 11.
4. Goto Y, Ohori M, Arakawa A, Kattan MW, Wheeler TM, Scardino PT. Distinguishing clinically important from unimportant prostate cancers before treatment: Value of systematic biopsies. J Urol 1996 156 : 1059 63.
5. Irwin MB, Trapasso JG. Identification of insignificant prostate cancers: Analysis of preoperative parameters. Urology 1994 44 : 862 7 discussion 67-8.
6. Noguchi M, Stamey TA, McNeal JE, Yemoto CM. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: Lack of prediction of tumor significance for men with nonpalpable prostate cancer. J Urol 2001 166 : 104 9 discussion 9-10.
7. Augustin H, Hammerer PG, Graefen M et al. Insignificant prostate cancer in radical prostatectomy specimen: Time trends and preoperative prediction. Eur Urol 2003 43 : 455 60.
8. Dugan JA, Bostwick DG, Myers RP, Qian J, Bergstralh EJ, Oesterling JE. The definition and preoperative prediction of clinically insignificant prostate cancer. JAMA 1996 275 : 288 94.
9. Elgamal AA, Van Poppel HP, Van de Voorde WM, Van Dorpe JA, Oyen RH, Baert LV. Impalpable invisible stage T1c prostate cancer: Characteristics and clinical relevance in 100 radical prostatectomy specimens - A different view. J Urol 1997 157 : 244 50.
10. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994 271 : 368 74.
11. Stamey TA. More information on prostate specific antigen and prostate cancer. J Urol 2003 170 : 457 8.
12. Kattan MW, Eastham JA, Wheeler TM et al. Counseling men with prostate cancer: A nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol 2003 170 : 1792 7.
13. Furusato B, Rosner IL, Osborn D et al. Do patients with low volume prostate cancer have prostate specific antigen recurrence following radical prostatectomy? J Clin Pathol 2008 61 : 1038 40.
14. Desai A, Wu H, Sun L et al. Complete embedding and close step-sectioning of radical prostatectomy specimens both increase detection of extra-prostatic extension, and correlate with increased disease-free survival by stage of prostate cancer patients. Prostate Cancer Prostatic Dis 2002 5 : 212 18.
15. Ochiai A, Trpkov K, Yilmaz A, Donnelly B, Babaian RJ. Validation of a prediction model for low volume/low grade cancer: Application in selecting patients for active surveillance. J Urol 2007 177 : 907 10.
16. Ts'o PO, Pannek J, Wang ZP, Lesko SA, Bova GS, Partin AW. Detection of intact prostate cancer cells in the blood of men with prostate cancer. Urology 1997 49 : 881 5.
17. Wang ZP, Eisenberger MA, Carducci MA, Partin AW, Scher HI, Ts'o PO. Identification and characterization of circulating prostate carcinoma cells. Cancer 2000 88 : 2787 95.
18. Tkaczuk KH, Goloubeva O, Tait NS et al. The significance of circulating epithelial cells in Breast Cancer patients by a novel negative selection method. Breast Cancer Res Treat 2008 111 : 355 64.
19. Cheng L, Jones TD, Pan CX, Barbarin A, Eble JN, Koch MO. Anatomic distribution and pathologic characterization of small-volume prostate cancer (<0.5 ml) in whole-mount prostatectomy specimens. Mod Pathol 2005 18 : 1022 6.
20. Sengupta S, Blute ML, Bagniewski SM et al. After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer. BJU Int 2008 101 : 170 4.
21. van Oort IM, Kok DE, Kiemeney LA, Hulsbergen CA, Witjes JA. A single institution experience with biochemical recurrence after radical prostatectomy for tumors that on pathology are of small volume or 'insignificant'. Urol Oncol 2009 27 : 509 13.
22. Panteleakou Z, Lembessis P, Sourla A et al. Detection of circulating tumor cells in prostate cancer patients: Methodological pitfalls and clinical relevance. Mol Med 2009 15 : 101 14.
23. Davis JW, Nakanishi H, Kumar VS et al. Circulating tumor cells in peripheral blood samples from patients with increased serum prostate specific antigen: Initial results in early prostate cancer. J Urol 2008 179 : 2187 91.